Selected references
- Fan S, Ma IX, Wang C, et al. p300 modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002;62:141–51
- Fan S, Ma YX, Wang C, et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001;20:77–87
- Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gate-keepers and caretakers. Nature 1997;386:761,763
Further reading
- Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669–71
- Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablasion. Nature 2001;411: 1017–21
- Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Con-sortium. Lancet 1994;343:692–5
- Huang J, Li X, Yi P et al. Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes. Mol Cell Endocrinol 2004;218: 65–78
- Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:2918–21
- Shih HA, Couch FJ, Nathanson KL, et al. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 2002;20:994–9